# Combination of TATE and PD-1 Inhibitor in Liver Cancer

Source: https://onco.cc/trials/nct03259867/  
OnCo record `nct03259867` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab in hepatocellular carcinoma, run by Teclison Ltd., now recruiting.

## Summary

Combination of TATE and PD-1 Inhibitor in Liver Cancer is a phase 2 interventional study registered as NCT03259867 by Teclison Ltd., with 54 participants planned, started 2017-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization. Conditions listed: Hepatocellular Carcinoma, Gastric Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03259867
- Phase: 2
- Setting: Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody
- Sponsor: Teclison Ltd.
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT03259867: https://clinicaltrials.gov/study/NCT03259867

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct03259867.json